Using breast cancer mRNA expression data from the TCGA project, we determined that activated PR target genes were significantly upregulated in ILC as well as clinically determined PR-negative luminal patient samples (compared to gene sets specifically regulated by inactive or stabilized and abundant receptors). This evidence concerns the gene PGR and breast cancer.